Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 2:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CBD 20 mg Clear all
Completed Phase 2 Interventional

12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa

NCT00456794
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Istradefylline (KW-6002)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 28, 2026, 2:11 AM EDT
Completed Phase 3 Interventional Results available

GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

NCT02224703
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P, Placebo Control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 28, 2026, 2:11 AM EDT
Completed Phase 3 Interventional Results available

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

NCT02091375
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P 20 mg/kg/day Dose, Placebo control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
13
States / cities
Miami, Florida • Orlando, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 28, 2026, 2:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Effects of CBD Products on Anxiety Among U.S. Women

NCT05108220
View directory record Official record
Conditions
Anxiety, Generalized Anxiety Disorder
Interventions
Cannabidiol (CBD)- containing consumer products
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
24 Years to 44 Years · Female only
Enrollment
1,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 28, 2026, 2:11 AM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

NCT02091206
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P 5 mg/kg/day Dose, Placebo control, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
4 Years to 10 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 28, 2026, 2:11 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome

NCT05098509
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
RAD011, Placebo
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Sep 28, 2026, 2:11 AM EDT
Completed Phase 1 Interventional

Safety Study of TPI-287 to Treat CBS and PSP

NCT02133846
View directory record Official record
Conditions
Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Interventions
TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Sep 28, 2026, 2:11 AM EDT
Terminated Phase 4 Interventional Results available

Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain

NCT03891264
View directory record Official record
Conditions
Back Pain, Low
Interventions
Cannabidiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Sep 28, 2026, 2:11 AM EDT
Completed Phase 3 Interventional Results available

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

NCT00360568
View directory record Official record
Conditions
Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 28, 2026, 2:11 AM EDT
Completed Phase 3 Interventional

A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa

NCT00199420
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Istradefylline (KW-6002)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 28, 2026, 2:11 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

NCT05288283
View directory record Official record
Conditions
Seizures Associated With EMAS
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 28, 2026, 2:11 AM EDT
Terminated Phase 2 Interventional Results available

Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures

NCT03336242
View directory record Official record
Conditions
Childhood Absence Epilepsy
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
3 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 28, 2026, 2:11 AM EDT
Completed Phase 2 Interventional Results available

Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome

NCT04447846
View directory record Official record
Conditions
Sturge-Weber Syndrome
Interventions
Cannabidiol
Drug
Lead sponsor
Anne Comi, MD
Other
Eligibility
3 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Sep 28, 2026, 2:11 AM EDT
Completed Phase 1Phase 2 Interventional

NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

NCT05083260
View directory record Official record
Conditions
Parkinson Disease
Interventions
NE3107, placebo
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
16
States / cities
Englewood, Colorado • Boca Raton, Florida • Hallandale, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 28, 2026, 2:11 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism

NCT04517799
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Epidiolex, placebo oral solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
7 Years to 14 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 28, 2026, 2:11 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Topical Cannabidiol Cream and Post-exercise Recovery

NCT05044936
View directory record Official record
Conditions
Muscle Damage
Interventions
Cannabidiol Oil, Resistance Exercise
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 28, 2026, 2:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

NCT02324673
View directory record Official record
Conditions
Seizures
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
1 Year to 17 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Pensacola, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 28, 2026, 2:11 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

NCT02799381
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
Optimized antiparkinsonian treatment, Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy ambulatory infusion pump, Percutaneous endoscopic gastrostomy tube, Jejunal extension tube
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Port Charlotte, Florida • Round Rock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Sep 28, 2026, 2:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cannabidiol and Focus Study (CBD-Focus)

NCT05189275
View directory record Official record
Conditions
Healthy
Interventions
Daily Beverage Intervention
Dietary Supplement
Lead sponsor
University of Northern Colorado
Other
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Greeley, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Sep 28, 2026, 2:11 AM EDT
Not yet recruiting Phase 3 Interventional

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

NCT07148206
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 28, 2026, 2:11 AM EDT
Completed Phase 2 Interventional

The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy

NCT04088929
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
CBD
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Sterling Heights, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 28, 2026, 2:11 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving

NCT07148843
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification, Craving
Interventions
Cannabidiol (CBD), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 28, 2026, 2:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions

NCT06192589
View directory record Official record
Conditions
Cannabidiol, Drug Induced Liver Injury, Drug Interaction
Interventions
Cannabidiol, Placebo, Citalopram, Morphine
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 28, 2026, 2:11 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00660387
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo Gel, Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • Fountain Valley, California • Oceanside, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 28, 2026, 2:11 AM EDT